Launch of Mucodis® Dermal Spray

Quantum Pharma Plc

(the 'Group')

Launch of Mucodis® Dermal Spray

Quantum Pharma Plc (AIM:QP.), the growing, service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, is pleased to announce that Colonis, part of its recently formed Niche Pharmaceuticals division, has launched Mucodis® Dermal Spray. The spray is part of the Mucodis® range of in-licensed patented medical devices, which focus on treating some of the side effects experienced by patients undergoing the treatment of cancer.

Mucodis® Dermal Spray helps to prevent and treat radiation-induced dermatitis ("Radiodermatitis"). Radiodermatitis is a side effect of radiotherapy which can cause a range of dermal disorders from inflammation of the skin to the development of necrosis and skin peeling. The development and severity of radiodermatitis depends on multiple patient and treatment factors which include the total radiation dose administered, the duration of radiotherapy, and concomitant treatment with chemotherapy1. All patients receiving radiotherapy are therefore at a potential risk of developing some degree of radiodermatitis with approximately 85% of patients experiencing a moderate to severe skin reaction2.

352,000 patients in the UK are diagnosed annually with cancer and many experience painful or unpleasant side effects as they progress with their treatment3. The Mucodis® range provides the NHS with prescribable products to address a number of the side effects associated with cancer treatments including mucositis, radiation-induced dermatitis, vulvovaginitis and proctitis. Colonis has been granted an exclusive distribution licence for these products for five years, with an option to extend beyond this initial period.

Andrew Scaife, Chief Executive of Quantum Pharma Plc, commented: "Radiodermatitis is an unpleasant and painful side effect of cancer treatment and we are delighted to launch Mucodis® Dermal Spray to help treat these symptoms. We are excited by the potential that the Mucodis® range offers the NHS and patients. There is a clear unmet need for this type of relief and we are confident that our products will have a significant effect on improving the patient's quality of life."

Footnotes:

1. https://www.ons.org/practice-resources/pep/radiodermatitis

2. Salvo, N. et al. Prophylaxis and management of acute radiation-induced skin reactions: A systematic review of the literature. Curr Oncol. 2010: 17(4); 94-112.

3. Cancer Research UK (accessed June 2016)

- Ends -

For further information:

Notes to Editors

Quantum Pharma Plc is a service-led, niche pharmaceutical developer, manufacturer and supplier to the retail pharmacy, pharmaceutical wholesaler, hospital, homecare and care home markets. Quantum Pharma operates through three divisions, offering a portfolio of innovative and complementary products and services.

Specials comprises four business units (Quantum Pharmaceutical, UL Medicines, NuPharm and Quantum Aseptics Services), which manufacture, procure and supply unlicensed medicines (specials) and special obtains. In response to a request from a prescriber for a bespoke medicine or special product to optimise patient treatment, the division manufactures, procures and supplies bespoke specials; batch made specials; aseptically prepared sterile intravenous medicines; imported medicines and special obtain products. With an expansive portfolio of products, Quantum is a trusted partner to the majority of large retail pharmacy chains in the UK, as well as pharmaceutical wholesalers, hospitals, independent pharmacies and dispensing doctors.  The division offers an unrivalled and constantly expanding range of products. It has a customer-focused, service-driven business model, which provides shorter lead times than any of its competitors.

Niche Pharmaceuticals comprises three business units (Colonis, Lamda and PERN Consumer Products) which develop and commercialise niche pharmaceuticals. This division is a product development and commercialisation business focusing on taking niche drugs through the regulatory pathway to achieve regulated status (licensed product or medical device). The division uses the excellent visibility of trends in the UK pharmacy and hospital markets gained through our Specials and Medication Adherence divisions, to allow early identification of the market opportunity to take products from unlicensed (special) status to licensed status. The division has a growing portfolio and pipeline of products that fit this unlicensed to licensed pathway, as well as complementary generic, generic plus or medical devices intended to meet unmet patient needs across a number of therapeutic areas.

Medication Adherence comprises two business units (Biodose® and Biodose Services®) which provide products and services to enhance the likelihood of a patient adhering to a medication regime, patient-focused homecare services and services to pharmaceutical companies. It owns Biodose®, the only medication delivery system on the market that accommodates both liquid and solid doses. Biodose Connect™ takes patient safety and adherence to the next level by enabling remote monitoring of adherence to medication regimes. The division also operates a range of specialist patient-focused homecare services to the NHS, private clinics and pharmaceutical companies across the UK and provides the Group with exposure to the homecare and supported living sectors of the care pathway complementing the focus of the remainder of the Group.

For further information, please visit www.quantumpharmaplc.com.